Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 1998

View Archived Issues

Mechanisms mediating the effects of ADM on cardiac contractility

Neurotropin, a therapeutic agent for PGE1 therapy-associated penile pain

SmithKline Beecham provides update on product pipeline and future directions

Company Profile: Myelos Neurosciences

Unexpected results from a study of gene therapy for rheumatoid arthritis

mRNA splicing appears to trigger metastasis in prostate cancer

Collaborations formed to further development of memantine

ImmuLogic evaluates cocaine vaccine in phase I

Sheffield signs option agreement with Zambon for MSI delivery system

Shire to market Fidia's new osteoarthritis treatment

Cypros receives notice of allowance on patent claiming Cordox for asthma

New data reported for donepezil hydrochloride

Tricyclic compounds inhibiting protein farnesyltransferase claimed by Schering-Plough

Synthelabo discloses new benzimidazoles for urinary incontinence

New antiparasitic compounds from Kitasato Institute

Tobishi synthesizes new CCK-A antagonist for treatment of pancreatitis

MS&D discovers agents for safely enhancing cognition

Novel ACAT inhibitor presented at Japanese congress

Dainippon presents a BZP inverse agonist for the treatment of dementia

Heterocyclic tachykinin antagonists from Sanofi

Phase I data reported for antitumor bisnaphthalimide DMP-840

New water-soluble dolastatin derivatives with potent antitumor activity

Atlantic's 2-5A antisense compound shows excellent anti-RSV activity in vitro

Sanofi discloses cGMP PDE inhibitors for cardiovascular indications

Orphan drug designation granted for Xerecept

Trega initiates phase I testing of HP-228 using novel pulmonary delivery system

More retinoids emerge from the Allergan pipeline

Amarillo Biosciences receives notice of allowance for U.S. patent

Repligen receives Phase II SBIR grant for angiogenesis research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...